JPS60163814A - Glucocorticoid antagonistic agent - Google Patents

Glucocorticoid antagonistic agent

Info

Publication number
JPS60163814A
JPS60163814A JP1979684A JP1979684A JPS60163814A JP S60163814 A JPS60163814 A JP S60163814A JP 1979684 A JP1979684 A JP 1979684A JP 1979684 A JP1979684 A JP 1979684A JP S60163814 A JPS60163814 A JP S60163814A
Authority
JP
Japan
Prior art keywords
glucocorticoid
invasion
melatonin
day
treating
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP1979684A
Inventor
Wataru Mori
Original Assignee
Wataru Mori
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wataru Mori filed Critical Wataru Mori
Priority to JP1979684A priority Critical patent/JPS60163814A/en
Publication of JPS60163814A publication Critical patent/JPS60163814A/en
Application status is Expired - Lifetime legal-status Critical

Links

Abstract

PURPOSE: The titled antagonistic agent, containing melatonin of pineal body hormone as an active constituent, capable of antagonizing the action of glucocorticoid, and useful for preventing and treating an invasion state caused by mental factors, hemorrhage, external wounds, infection, etc.
CONSTITUTION: A glucocorticoid antagonistic agent containing melatonin; N-[2- (5-methoxyindol-3-yl)ethyl] acetamide of the formula. If invasion is excessive, adrenocortical function is abnormally exacerbated to cause excess secretion of the glucocorticoid and incur remarkable consumption of physical strength. The melatonin is found to be capable of controlling the excess state of the glucocorticoid and has anti-invasion action and useful for preventing and treating the invasion state caused by delivery, external wounds, surgical operation, etc. The dose thereof is 1W500mg/day for oral administration and 1W30mg/day for intravenous injection. The above-mentioned agent is safe with low toxicity.
COPYRIGHT: (C)1985,JPO&Japio
JP1979684A 1984-02-06 1984-02-06 Glucocorticoid antagonistic agent Expired - Lifetime JPS60163814A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP1979684A JPS60163814A (en) 1984-02-06 1984-02-06 Glucocorticoid antagonistic agent

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP1979684A JPS60163814A (en) 1984-02-06 1984-02-06 Glucocorticoid antagonistic agent

Publications (1)

Publication Number Publication Date
JPS60163814A true JPS60163814A (en) 1985-08-26

Family

ID=12009306

Family Applications (1)

Application Number Title Priority Date Filing Date
JP1979684A Expired - Lifetime JPS60163814A (en) 1984-02-06 1984-02-06 Glucocorticoid antagonistic agent

Country Status (1)

Country Link
JP (1) JPS60163814A (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004019935A1 (en) * 2002-08-29 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
US7635711B2 (en) 2004-12-27 2009-12-22 Boehringer-Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US7932392B2 (en) 2002-03-26 2011-04-26 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US8268859B2 (en) 2008-06-06 2012-09-18 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7932392B2 (en) 2002-03-26 2011-04-26 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US8212040B2 (en) 2002-03-26 2012-07-03 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and thereof
EA011095B1 (en) * 2002-08-29 2008-12-30 Бёрингер Ингельхайм Фармасьютиклз, Инк. 3-(sulfonamidoethyl)-indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
WO2004019935A1 (en) * 2002-08-29 2004-03-11 Boehringer Ingelheim Pharmaceuticals, Inc. -3 (sulfonamidoethyl) -indole derivaties for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
JP2006504681A (en) * 2002-08-29 2006-02-09 ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド 3- (Sulfonamidoethyl) -indole derivatives for use as glucocorticoid mimetics in the treatment of inflammatory, allergic and proliferative diseases
US7795272B2 (en) 2004-03-13 2010-09-14 Boehringer Ingelheim Pharmaceutical, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof
US7635711B2 (en) 2004-12-27 2009-12-22 Boehringer-Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US7741361B2 (en) 2004-12-27 2010-06-22 Boehringer Ingelheim Pharmaceuticals, Inc. Glucocorticoid mimetics, methods of making them, pharmaceutical compositions, and uses thereof
US8268859B2 (en) 2008-06-06 2012-09-18 Boehringer Ingelheim International Gmbh Glucocorticoid mimetics, methods of making them, pharmaceutical compositions and uses thereof

Similar Documents

Publication Publication Date Title
JO2475B1 (en) Glucokinase Activators
JO1502B1 (en) Novel pharmacological compounds
TW376319B (en) Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
CA2078347A1 (en) Use of copper(ii) containing compounds to accelerate wound healing
JPH01170476A (en) Medical device for transdermal medication of highly ionized and fat insoluble medicine
CA2195027A1 (en) HIV Protease Inhibitors Useful for the Treatment of AIDS
EA200000468A1 (en) Therapeutic composition for the administration of tolterodine with controlled delivery
NZ535197A (en) Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
CA2045077A1 (en) Anti-epileptics
MX9602656A (en) Transdermal device containing polyvinylpyrrolidone as solubility enhancer.
MXPA02007690A (en) Controlled release compositions containing opioid agonist and antagonist.
JPS63258841A (en) Tyrosine derivative and use thereof
NZ336055A (en) An oral sustained release formulation of opioids
CA2198916A1 (en) Delivery of solid drug compositions
CA2029420A1 (en) Pharmaceutical compositions and methods for inhibition of maillard's reaction
RU94026082A (en) Use of wortmannin and its analogs for preparing preparation for inhibition of phosphatidylinositol-3 kinase in mammalian and for preparing preparation for treatment of phosphatidylinositol-3 kinase-dependent states
JPH0215029A (en) Quinolidinone compound or antiulcer agent containing salt thereof
GEP20012376B (en) Bicyclic Pyrimidine Derivatives Capable of InhibitingTyrosine Kinases of the Epidermal Growth Factor, Pharmaceutical Composition Containing the Same and Methods for Treatment
HU9203342D0 (en) Powder-like medical preparatives with regulated delivering of active substance
EP0903148A3 (en) Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
CA2105165A1 (en) Dosage form for a delayed drug-delivery
CA2039655A1 (en) Sheet for containing micronized powdered medicament
WO1999015156B1 (en) Inhibition of crystallization in transdermal devices
NZ330369A (en) aqueous medicaments containing 9-hydroxy-risperidone fatty acid ester
CO5590958A2 (en) Nonnucleoside reverse traqnscriptasa

Legal Events

Date Code Title Description
EXPY Cancellation because of completion of term